Company News

  • Reset
GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection
View
GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2
View
GOLDEN, Colo. — July 19, 2022 — PharmaJet® , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022. The presentation, entitled Advances in
View
GOLDEN, Colo. — July 5, 2022—PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June.
View
GOLDEN, Colo. — June 21, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, Nykode Therapeutics announced positive interim results from its phase 2 trial of their novel candidate, VB10.16, in
View
GOLDEN, Colo. — June 7, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that the phase 3 clinical study sponsored by their partner, Zydus Lifesciences, has been published in The Lancet. The
View
GOLDEN, Colo. — May 24, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 Million grant from the National Institute on
View
GOLDEN, Colo. — April 27, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that their latest research results were presented at the World Vaccine Congress on April 20.  The presentation, entitled Benefits of
View
GOLDEN, Colo. — February 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia, has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. Interim safety data of COVIGEN,
View
Menu